{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:44:30Z","timestamp":1777045470647,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"nippon shinyaku co., ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Obinutuzumab, a Type II anti-CD20 antibody, is used to treat follicular lymphoma. A major mode of action of obinutuzumab is antibody-dependent cellular cytotoxicity (ADCC). Knowledge of the mechanisms of resistance to obinutuzumab is important for the development of next-line strategies to follow obinutuzumab-containing therapy, including obinutuzumab retreatment. Unfortunately, the mechanisms by which tumor cells acquire resistance to ADCC are still poorly understood. To address this, we examined the mechanisms of resistance to obinutuzumab-induced ADCC and the combination efficacy of obinutuzumab and clinically available agents in the established resistant cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>We established cells resistant to obinutuzumab-induced ADCC using the non-Hodgkin lymphoma cell line RL and examined their mechanisms of resistance and the combination efficacy of obinutuzumab and clinically available agents. Comprehensive analysis by RNA\u00a0sequencing of resistance mechanisms revealed that abnormal Fas signaling decreased sensitivity to ADCC in resistant clones. Combination treatment with prednisolone, a component of CHOP and CVP, was found to enhance ADCC sensitivity of RL cells and resistant clones and to significantly suppress tumor growth in xenograft models. Treatment with prednisolone upregulated expression of CD20 and an apoptosis-inducing protein BIM, which might augment perforin\/granzyme B-mediated cell death. Furthermore, pretreatment of the effector cells with bendamustine enhanced ADCC activity, and treatment with obinutuzumab plus bendamustine showed significant antitumor efficacy in xenograft models. It was speculated that bendamustine upregulates ADCC activity by potentiating granules-mediated cell killing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study revealed a novel mechanism underlying obinutuzumab-induced ADCC resistance and indicated that ADCC resistance could be overcome by combining obinutuzumab with prednisolone or bendamustine. This study provides a scientific rationale for obinutuzumab-retreatment in combination with clinically available chemotherapeutic agents for obinutuzumab resistant follicular lymphoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11033-022-07280-w","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T08:02:34Z","timestamp":1645862554000},"page":"4421-4433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies"],"prefix":"10.1007","volume":"49","author":[{"given":"Natsumi","family":"Kawasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1157-649X","authenticated-orcid":false,"given":"Yoriko","family":"Yamashita-Kashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Yoshiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"issue":"3","key":"7280_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ejh.13271","volume":"103","author":"R Dada","year":"2019","unstructured":"Dada R (2019) Diagnosis and management of follicular lymphoma: a comprehensive review. Eur J Haematol 103(3):152\u2013163. https:\/\/doi.org\/10.1111\/ejh.13271","journal-title":"Eur J Haematol"},{"issue":"1","key":"7280_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, Lopez-Guillermo A et al (2019) Follicular lymphoma. Nat Rev Dis Primers 5(1):83. https:\/\/doi.org\/10.1038\/s41572-019-0132-x","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"7280_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z et al (2020) Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10(7):74. https:\/\/doi.org\/10.1038\/s41408-020-00340-z","journal-title":"Blood Cancer J"},{"issue":"2","key":"7280_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","volume":"34","author":"K Tobinai","year":"2017","unstructured":"Tobinai K, Klein C, Oya N, Fingerle-Rowson G (2017) A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther 34(2):324\u2013356. https:\/\/doi.org\/10.1007\/s12325-016-0451-1","journal-title":"Adv Ther"},{"issue":"30","key":"7280_CR5","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O et al (2015) Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol 33(30):3467\u20133474. https:\/\/doi.org\/10.1200\/JCO.2014.59.2139","journal-title":"J Clin Oncol"},{"issue":"8","key":"7280_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/s1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K et al (2016) Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17(8):1081\u20131093. https:\/\/doi.org\/10.1016\/s1470-2045(16)30097-3","journal-title":"Lancet Oncol"},{"issue":"14","key":"7280_CR7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377(14):1331\u20131344. https:\/\/doi.org\/10.1056\/NEJMoa1614598","journal-title":"N Engl J Med"},{"issue":"3","key":"7280_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3109\/10428190903503404","volume":"51","author":"A Johnston","year":"2010","unstructured":"Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, Michallet AS, Traulle C, Salles G et al (2010) Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymphoma 51(3):399\u2013405. https:\/\/doi.org\/10.3109\/10428190903503404","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"7280_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/abt\/tby002","volume":"1","author":"D Zahavi","year":"2018","unstructured":"Zahavi D, AlDeghaither D, O\u2019Connell A, Weiner LM (2018) Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther 1(1):7\u201312. https:\/\/doi.org\/10.1093\/abt\/tby002","journal-title":"Antib Ther"},{"issue":"22","key":"7280_CR10","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E Mossner","year":"2010","unstructured":"Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22):4393\u20134402. https:\/\/doi.org\/10.1182\/blood-2009-06-225979","journal-title":"Blood"},{"issue":"22","key":"7280_CR11","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Martinez-Lostao","year":"2015","unstructured":"Martinez-Lostao L, Anel A, Pardo J (2015) How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res 21(22):5047\u20135056. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0685","journal-title":"Clin Cancer Res"},{"key":"7280_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fimmu.2015.00202","volume":"6","author":"A Gras Navarro","year":"2015","unstructured":"Gras Navarro A, Bjorklund AT, Chekenya M (2015) Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol 6:202. https:\/\/doi.org\/10.3389\/fimmu.2015.00202","journal-title":"Front Immunol"},{"issue":"11","key":"7280_CR13","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/labinvest.2009.91","volume":"89","author":"WA Boivin","year":"2009","unstructured":"Boivin WA, Cooper DM, Hiebert PR, Granville DJ (2009) Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 89(11):1195\u20131220. https:\/\/doi.org\/10.1038\/labinvest.2009.91","journal-title":"Lab Invest"},{"key":"7280_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.412","volume":"7","author":"MK Evans","year":"2016","unstructured":"Evans MK, Sauer SJ, Nath S, Robinson TJ, Morse MA, Devi GR (2016) X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis 7:e2073. https:\/\/doi.org\/10.1038\/cddis.2015.412","journal-title":"Cell Death Dis"},{"issue":"11","key":"7280_CR15","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00262-012-1249-x","volume":"61","author":"R Yoshida","year":"2012","unstructured":"Yoshida R, Tazawa H, Hashimoto Y, Yano S, Onishi T, Sasaki T et al (2012) Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells. Cancer Immunol Immunother 61(11):1905\u20131916. https:\/\/doi.org\/10.1007\/s00262-012-1249-x","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"7280_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/2326-6066.CIR-18-0266","volume":"7","author":"DS Aldeghaither","year":"2019","unstructured":"Aldeghaither DS, Zahavi DJ, Murray JC, Fertig EJ, Graham GT, Zhang YW et al (2019) A mechanism of resistance to antibody-targeted immune attack. Cancer Immunol Res 7(2):230\u2013243. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0266","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"7280_CR17","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1158\/1078-0432.CCR-10-2927","volume":"17","author":"Y Yamashita-Kashima","year":"2011","unstructured":"Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M et al (2011) Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 17(15):5060\u20135070. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2927","journal-title":"Clin Cancer Res"},{"issue":"4","key":"7280_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1101\/gr.213546.116","volume":"27","author":"JS Brammeld","year":"2017","unstructured":"Brammeld JS, Petljak M, Martincorena I, Williams SP, Alonso LG, Dalmases A et al (2017) Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations. Genome Res 27(4):613\u2013625. https:\/\/doi.org\/10.1101\/gr.213546.116","journal-title":"Genome Res"},{"issue":"2","key":"7280_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3892\/ijo.2017.4036","volume":"51","author":"C Masuda","year":"2017","unstructured":"Masuda C, Yanagisawa M, Yorozu K, Kurasawa M, Furugaki K, Ishikura N et al (2017) Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. Int J Oncol 51(2):425\u2013434. https:\/\/doi.org\/10.3892\/ijo.2017.4036","journal-title":"Int J Oncol"},{"issue":"10","key":"7280_CR20","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","volume":"112","author":"MN Dworzak","year":"2008","unstructured":"Dworzak MN, Schumich A, Printz D, Potschger U, Husak Z, Attarbaschi A et al (2008) CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 112(10):3982\u20133988. https:\/\/doi.org\/10.1182\/blood-2008-06-164129","journal-title":"Blood"},{"issue":"3","key":"7280_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.exphem.2010.11.009","volume":"39","author":"N Jiang","year":"2011","unstructured":"Jiang N, Koh GS, Lim JY, Kham SK, Ariffin H, Chew FT et al (2011) BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp Hematol 39(3):321\u2013329, e321-323. https:\/\/doi.org\/10.1016\/j.exphem.2010.11.009","journal-title":"Exp Hematol"},{"issue":"12","key":"7280_CR22","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1182\/blood-2011-08-374199","volume":"119","author":"YT Bryceson","year":"2012","unstructured":"Bryceson YT, Pende D, Maul-Pavicic A, Gilmour KC, Ufheil H, Vraetz T et al (2012) A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 119(12):2754\u20132763. https:\/\/doi.org\/10.1182\/blood-2011-08-374199","journal-title":"Blood"},{"issue":"3","key":"7280_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nm.3442","volume":"20","author":"S Afshar-Sterle","year":"2014","unstructured":"Afshar-Sterle S, Zotos D, Bernard NJ, Scherger AK, Rodling L, Alsop AE et al (2014) Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med 20(3):283\u2013290. https:\/\/doi.org\/10.1038\/nm.3442","journal-title":"Nat Med"},{"issue":"3","key":"7280_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-2141.2010.08326.x","volume":"151","author":"M Scandurra","year":"2010","unstructured":"Scandurra M, Mian M, Greiner TC, Rancoita PM, De Campos CP, Chan WC et al (2010) Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP-21. Br J Haematol 151(3):221\u2013231. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08326.x","journal-title":"Br J Haematol"},{"issue":"1","key":"7280_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/hon.996","volume":"30","author":"J Harris","year":"2012","unstructured":"Harris J, Ibrahim H, Amen F, Karadimitris A, Naresh KN, Macdonald DH (2012) Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype. Hematol Oncol 30(1):8\u201312. https:\/\/doi.org\/10.1002\/hon.996","journal-title":"Hematol Oncol"},{"key":"7280_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fendo.2016.00031","volume":"7","author":"AM Xavier","year":"2016","unstructured":"Xavier AM, Anunciato AK, Rosenstock TR, Glezer I (2016) Gene expression control by glucocorticoid receptors during innate immune responses. Front Endocrinol (Lausanne) 7:31. https:\/\/doi.org\/10.3389\/fendo.2016.00031","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"26","key":"7280_CR27","doi-asserted-by":"publisher","first-page":"23861","DOI":"10.1074\/jbc.M301843200","volume":"278","author":"Z Wang","year":"2003","unstructured":"Wang Z, Malone MH, He H, McColl KS, Distelhorst CW (2003) Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 278(26):23861\u201323867. https:\/\/doi.org\/10.1074\/jbc.M301843200","journal-title":"J Biol Chem"},{"issue":"40","key":"7280_CR28","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1073\/pnas.0606176103","volume":"103","author":"J Kuroda","year":"2006","unstructured":"Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al (2006) Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103(40):14907\u201314912. https:\/\/doi.org\/10.1073\/pnas.0606176103","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"7280_CR29","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1371\/journal.pmed.0040316","volume":"4","author":"MS Cragg","year":"2007","unstructured":"Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A (2007) Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4(10):1681\u20131689. https:\/\/doi.org\/10.1371\/journal.pmed.0040316 (discussion 1690)","journal-title":"PLoS Med"},{"issue":"5","key":"7280_CR30","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.3892\/or.2014.3077","volume":"31","author":"Y Seo","year":"2014","unstructured":"Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T et al (2014) Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS\/BRAF mutational status in colorectal cancer. Oncol Rep 31(5):2115\u20132122. https:\/\/doi.org\/10.3892\/or.2014.3077","journal-title":"Oncol Rep"},{"key":"7280_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.critrevonc.2015.09.001","volume":"97","author":"N Seyfizadeh","year":"2016","unstructured":"Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta-Yepez S (2016) A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Crit Rev Oncol Hematol 97:275\u2013290. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.09.001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"7280_CR32","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-20-0864","volume":"20","author":"T Fujimura","year":"2021","unstructured":"Fujimura T, Yamashita-Kashima Y, Kawasaki N, Yoshiura S, Harada N, Yoshimura Y (2021) Obinutuzumab in combination with chemotherapy enhances direct cell death in CD20-positive obinutuzumab-resistant non-Hodgkin lymphoma cells. Mol Cancer Ther 20(6):1133\u20131141. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0864","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"7280_CR33","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1053\/j.seminhematol.2011.03.003","volume":"48","author":"LM Leoni","year":"2011","unstructured":"Leoni LM, Hartley JA (2011) Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol 48(Suppl 1):S12-23. https:\/\/doi.org\/10.1053\/j.seminhematol.2011.03.003","journal-title":"Semin Hematol"},{"key":"7280_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.86","volume":"5","author":"H Saito","year":"2015","unstructured":"Saito H, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto K et al (2015) Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J 5:e362. https:\/\/doi.org\/10.1038\/bcj.2015.86","journal-title":"Blood Cancer J"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07280-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-07280-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07280-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T22:42:53Z","timestamp":1657233773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-07280-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["7280"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-07280-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,26]]},"assertion":[{"value":"22 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of Chugai Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee at Chugai Pharmaceutical Co., Ltd., which is an institute accredited by AAALAC international and conformed to the Guide for the Care and Use of Laboratory Animals published by Institute of Laboratory Animal Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}